Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ION717 in Prion Disease
NCT06153966Phase 2Active, not recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jan 2024
- Primary completion
- Apr 2027
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of ION717 in Prion Disease (PD) (3 arms), sponsored by Ionis Pharmaceuticals. Primary endpoint: Incidence of treatment-emergent adverse events. Started Jan 2024; status: active, not recruiting.
02
Drugs
ION717
03
Conditions
Prion Disease (PD)
Beyond the preview
Go deeper on NCT06153966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06153966.